���重受体激动剂的分子设计 — Explained

By Editorial Desk · published 2025-12-10 · last reviewed 2026-01-08 · News

The short version of 肠促胰素 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Discovery and Receptor Profile

Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.

Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.

Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.

Retatrutide at a glance

Further detail

Harvard psychiatrist Lester Grinspoon then sued the DEA, claiming that the DEA had ignored the medical uses of MDMA, and the federal court sided with Grinspoon, calling Lawn's argument "strained" and "unpersuasive", and vacated MDMA's Schedule I status. Despite this, less than a month later Lawn reviewed the evidence and reclassified MDMA as Schedule I again, claiming that the expert testimony of several psychiatrists claiming over 200 cases where MDMA had been used in a therapeutic context with positive results could be dismissed because they were not published in medical journals. In 2017, the FDA granted breakthrough therapy designation for its use with psychotherapy for PTSD. However, this designation has been questioned and problematized.

== PIDD1 and Cancer == Tumor protein p53 (TP53, often referred to as p53) regulates a sophisticated network of tumor-suppressive responses to prevent the growth and persistence of cells with extra centrosomes. These responses include halting cell division, promoting cellular senescence, initiating controlled cell death, and, in instances of whole-genome duplication, activating immune surveillance by cytotoxic T cells. CASP2 plays a very important role in regulation and activation of p53 in response to extra centrosomes. Its activation is dependent on the formation of the "PIDDosome," a large protein complex that includes p53-induced death domain protein 1 (PIDD1), CASP2, and [RIPK1]] containing a death domain (CRADD, commonly referred to as RAIDD). This complex enables CASP2 to inactivate MDM2, a key inhibitor of p53, thereby promoting the activation of p53. In a study, Evans and colleagues conducted a genome-wide CRISPR-Cas9 knockout screen using immortalized retinal pigment epithelial cells (hTERT RPE-1), modified to overexpress PLK4, which induces centriole overduplication. The cells also had constant depletion of ubiquitin-specific peptidase 28 (USP28) and tripartite motif-containing 37 (TRIM37), in order to suppress pathways typically activated by centrosome loss. This screening identified 30 genes involved in halting the proliferation of hTERT RPE-1 cells with excess centrosomes (supetnumerary centrosomes), with 23 of these genes previously linked to centrosome-related functions.

== Common themes == Architect Richard Buday has contended that architectural works have been used to justify loyalty to an area's rulers, or to religious and spiritual figures. Buday suggests that "the Sphinx and the pyramids were outsized visual demands for respect and obedience to Pharaoh. The Parthenon was constructed for societal manipulation, as well as to honor a goddess (the temple's ornamentation reminded Athenians that their beating back of a Persian invasion was an act of divine intervention). Roman triumphal arches were self-aggrandizing demonstrations of rulers' might and superiority". Later in history, Buday writes that various leaders have invoked particular architectural styles to invoke connections with previous historical states and ideas which are associated with them, such as using ancient Greek and Roman imagery to convey the idea of democracy, or invoking similar classical architecture to denote imperial ambitions. In modern times, architecture is used to attract tourism.

Sources: en.wikipedia.org

Related pages on this site

• Reliable workbook
• Regional review
• Verified archive
• Technical overview
• Simple overview
• Professional archive
• Simple analysis
• Seasonal toolkit

Background from the literature

== External links == Quips article describing E3 Ligase function Archived 2012-11-30 at the Wayback Machine at PDBe Ubiquitin-Protein+Ligases at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 6.3.2.19

{\displaystyle {\begin{aligned}V=\left[H_{0}^{1}(\Omega )\right]^{d}&=\left\{\mathbf {v} \in \left[H^{1}(\Omega )\right]^{d}:\quad \mathbf {v} =\mathbf {0} {\text{ on }}\Gamma _{D}\right\},\\Q&=L^{2}(\Omega )\end{aligned}}}

Dr. Stone is an anime television series produced by TMS Entertainment based on the manga series of the same name written by Riichiro Inagaki and illustrated by Boichi. Set 3,700 years after a mysterious light turns every human on the planet into stone, genius boy Senku Ishigami emerges from his petrification into a "Stone World" and seeks to rebuild human civilization from the ground up. Dr. Stone's second season, titled Dr. Stone: Stone Wars, aired from January 14 to March 25, 2021. The season premiered on Tokyo MX and KBS in a dual simulcast, with other networks following at later timeslots. It focuses on the story of the "Stone Wars" arc from the manga, in which Senku and the Ishigami villagers of the Kingdom of Science go to war with Tsukusa's Kingdom of Strength. The season is streamed by Crunchyroll worldwide outside of Asia, while then-separate company Funimation produced a simuldub. The season ran for 11 episodes. A sequel was announced after second season finale. The English dub for Stone Wars aired on Adult Swim's Toonami programming block from May 16 to July 25, 2021. The opening theme song is "Rakuen" (楽園; lit. 'Paradise') performed by Fujifabric, while the ending theme song is "Koe?" (声?; lit. 'Voice?') performed by Hatena.

== Research == Schymanski's first research publications were from her undergraduate work when she worked on developing new metal-containing polymers which resulted in three lead author publications. As a graduate student, Schymanski started using information on the fragmentation pattern of organic compounds as a means to expand the identification of unknown compounds. Schymanski applied these novel methods to the identification of unknown organic compounds found in wastewater, and used data collectively gathered by the NORMAN Association to define barriers to the identification of unknown organic compounds in water. Identifying and tracking unknown organic compounds continues to be an avenue of research pursued by Schymanski and she is a co-author on a 2014 textbook describing these methods. In 2012, Schymanski and Steffen Neumann started the Critical Assessment of Small Molecule Identification (CASMI) contest that provided researchers with information about unknown organic compounds and challenged them to use automated computational tools identify the unknown compounds. The Metabolomics Society highlighted the 2012 contest in their newsletter. There have been multiple iterations of the contest, and Schymanski examined the results of the 2016 contest. Schymanski's research focuses on characterizing organic compounds found in wastewater and exposomics, or the science of compounds that people are exposed to over their lifetimes.

Sources: en.wikipedia.org

Frequently asked questions